Cheyne Capital Management (UK) LLP recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
STORNOWAY HOUSE LONDON, X0 SW1A 3DH
As of the latest 13F report, the guru’s equity portfolio contained 59 stocks valued at a total of $57.00Mil. The top holdings were ATVI(13.80%), CHK(6.51%), and GOLD(6.00%).
According to GuruFocus data, these were Cheyne Capital Management (UK) LLP’s top five trades of the quarter.
Switch Inc
The guru sold out of their 131,000-share investment in NYSE:SWCH. Previously, the stock had a 9.44% weight in the equity portfolio. Shares traded for an average price of $34.02 during the quarter.
On 02/10/2023, Switch Inc traded for a price of $34.25 per share and a market cap of $5.41Bil. The stock has returned 30.04% over the past year.
GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, Switch Inc has a price-earnings ratio of 22.56, a price-book ratio of 6.98, a EV-to-Ebitda ratio of 11.27 and a price-sales ratio of 8.67.
The price-to-GF Value ratio is 1.29, earning the stock a GF Value rank of 1.
CrowdStrike Holdings Inc
The guru sold out of their 12,400-share investment in NAS:CRWD. Previously, the stock had a 4.37% weight in the equity portfolio. Shares traded for an average price of $136.88 during the quarter.
On 02/10/2023, CrowdStrike Holdings Inc traded for a price of $108.96 per share and a market cap of $25.54Bil. The stock has returned -42.29% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, CrowdStrike Holdings Inc has a price-book ratio of 19.42, a EV-to-Ebitda ratio of -755.48 and a price-sales ratio of 12.97.
The price-to-GF Value ratio is 0.32, earning the stock a GF Value rank of 2.
Xenon Pharmaceuticals Inc
The guru established a new position worth 42,500 shares in NAS:XENE, giving the stock a 2.93% weight in the equity portfolio. Shares traded for an average price of $36.42 during the quarter.
On 02/10/2023, Xenon Pharmaceuticals Inc traded for a price of $39.53 per share and a market cap of $2.47Bil. The stock has returned 29.15% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, Xenon Pharmaceuticals Inc has a price-book ratio of 3.28, a EV-to-Ebitda ratio of -16.60 and a price-sales ratio of 161.49.
The price-to-GF Value ratio is 5.78, earning the stock a GF Value rank of 1.
RAPT Therapeutics Inc
The guru established a new position worth 71,828 shares in NAS:RAPT, giving the stock a 2.49% weight in the equity portfolio. Shares traded for an average price of $20.01 during the quarter.
On 02/10/2023, RAPT Therapeutics Inc traded for a price of $27.01 per share and a market cap of $917.39Mil. The stock has returned 20.31% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10. There is insufficient data to calculate the stock’s profitability rating.
In terms of valuation, RAPT Therapeutics Inc has a price-book ratio of 4.27, a EV-to-Ebitda ratio of -9.14 and a price-sales ratio of 350.80.
The price-to-GF Value ratio is 3.45, earning the stock a GF Value rank of 1.
Alpine Immune Sciences Inc
The guru established a new position worth 181,886 shares in NAS:ALPN, giving the stock a 2.34% weight in the equity portfolio. Shares traded for an average price of $6.39 during the quarter.
On 02/10/2023, Alpine Immune Sciences Inc traded for a price of $7.97 per share and a market cap of $365.94Mil. The stock has returned 10.43% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Alpine Immune Sciences Inc has a price-book ratio of 1.93, a EV-to-Ebitda ratio of -2.40 and a price-sales ratio of 7.53.
The price-to-GF Value ratio is 0.29, earning the stock a GF Value rank of 2.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
